Search results for "Apoptosis."

showing 10 items of 1794 documents

p53 Involvement in the control of murine hair follicle regression.

2001

p53 is a transcription factor mediating a variety of biological responses including apoptotic cell death. p53 was recently shown to control apoptosis in the hair follicle induced by ionizing radiation and chemotherapy, but its role in the apoptosis-driven physiological hair follicle regression (catagen) remains to be elucidated. Here, we show that p53 protein is strongly expressed and co-localized with apoptotic markers in the regressing hair follicle compartments during catagen. In contrast to wild-type mice, p53 knockout mice show significant retardation of catagen accompanied by significant decrease in the number of apoptotic cells in the hair matrix. Furthermore, p53 null hair follicles…

medicine.medical_specialtyTumor suppressor genemedicine.medical_treatmentDown-RegulationApoptosisBiologyPathology and Forensic MedicineTelogen effluviumMiceBcl-2-associated X proteinDownregulation and upregulationInternal medicineProto-Oncogene ProteinsmedicineAnimalsbcl-2-Associated X ProteinMice Knockoutintegumentary systemGrowth factorAlopecia areatamedicine.diseaseHair follicleCell biologyUp-RegulationMice Inbred C57BLEndocrinologymedicine.anatomical_structureInsulin-Like Growth Factor Binding Protein 3Proto-Oncogene Proteins c-bcl-2Knockout mousebiology.proteinCommentaryFemaleTumor Suppressor Protein p53Hair FollicleThe American journal of pathology
researchProduct

Effect of ovarian stimulation with recombinant LH/ FSH, recombinant FSH and human menopausal gonadotrophin (hMG) in reducing apoptosis rate in cumulu…

2013

medicine.medical_specialtybiologybusiness.industryObstetrics and GynecologyStimulationlaw.inventionRecombinant fshEndocrinologyReproductive MedicinelawApoptosisInternal medicineHMG-CoA reductasebiology.proteinmedicineRecombinant DNAovarian stimulation apoptosis cumulus cells ICSISettore BIO/06 - Anatomia Comparata E CitologiaMenotropinsbusinessFertility and Sterility
researchProduct

Regulation of Apoptosis in Endocrine Autoimmunity

2002

Dysregulation of apoptosis is associated with the pathogenesis of organ-specific autoimmune diseases, through altered target organ susceptibility. Apoptosis signaling pathways can be initiated through activation of death receptors such as Fas. A comparative analysis of the expression of Fas and FasL, the antiapoptotic molecule Bcl-2, and apoptosis in both thyrocytes and thyroid-infiltrating lymphocytes (TILs) from patients with either Graves' disease (GD) or Hashimoto's thyroiditis (HT) was performed. GD thyrocytes expressed less Fas than HT thyrocytes, whereas GD TILs had higher levels of Fas and FasL than HT TILs. GD thyrocytes expressed higher levels of Bcl-2 compared with HT thyrocytes.…

medicine.medical_specialtybusiness.industryGeneral NeuroscienceGraves' diseaseThyroidhemic and immune systemschemical and pharmacologic phenomenamedicine.diseaseFas receptormedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyFas ligandAutoimmunityEndocrinologymedicine.anatomical_structureHistory and Philosophy of ScienceApoptosisHormone receptorInternal medicinemedicinebusinessCell damageAnnals of the New York Academy of Sciences
researchProduct

Influence of Propofol on Neuronal Damage and Apoptotic Factors after Incomplete Cerebral Ischemia and Reperfusion in Rats

2004

Background Propofol reduces neuronal damage from cerebral ischemia when investigated for less than 8 postischemic days. This study investigates the long-term effects of propofol on neuronal damage and apoptosis-related proteins after cerebral ischemia and reperfusion. Methods Male Sprague-Dawley rats were randomly assigned as follows: group 1 (n = 32, control): fentanyl and nitrous oxide-oxygen; group 2 (n = 32, propofol): propofol and oxygen-air. Ischemia (45 min) was induced by carotid artery occlusion and hemorrhagic hypotension. Pericranial temperature and arterial blood gases were maintained constant. After 1, 3, 7, and 28 postischemic days, brains were removed, frozen, and sliced. Hi…

medicine.medical_specialtybusiness.industryIschemiaHippocampal formationmedicine.diseaseNeuroprotectionFentanylBrain ischemiaAnesthesiology and Pain MedicineEndocrinologyApoptosisAnesthesiaInternal medicinemedicineArterial bloodPropofolbusinessmedicine.drugAnesthesiology
researchProduct

Oral Idarubicin in Maintenance Therapy of Acute Myeloid Leukemia

2001

More than half of all acute myeloid leukaemia (AML) patients are over 60 years. The disease free survival (DFS) and overall survival (OS) rate of these patients is poor. These unsatisfactory results are associated with adverse cytogenetic characteristics, prior myelods-plasia, adverse phenotypic features, MDR and BCL2 overexpression. Furthermore a large fraction of patients achieving CR early relapses. This is due to two factors: acquired tumor cell drug resistance and tumor re-growth. Maintenance therapy could provide a means to keep leukemic growth under control. We enrolled 31 elderly previous responder patients to standard induction therapy to receive maintenance oral IDA 3mg/m2 daily d…

medicine.medical_specialtybusiness.industryMyeloid leukemiaDrug resistanceCell cycleGastroenterologyRegimenMaintenance therapyApoptosisInternal medicineToxicitymedicineIdarubicinbusinessmedicine.drug
researchProduct

Antiphosphatidylserine Antibodies Affect Rat Yolk Sacs in Culture: a Mechanism for Fetal Loss in Antiphospholipid Syndrome

2004

PROBLEM: A variety of reproductive impairments have been reported in the context of the antiphospholipid syndrome (APS). APS is associated with the presence of antibodies to negatively charged phospholipids that may affect the outcome of pregnancy. METHOD OF STUDY: Rat embryos were cultured within their yolk sacs. The effects of two antiphosphatidylserine monoclonal aPS antibodies (HL5B, RR7F) regarding their influence on growth and apoptotic events of the yolk sacs, as well as on growth and the morphology of the embryos, were studied. RESULTS: Exposure of rat embryos and their yolk sacs to aPS inhibited yolk sac growth. Moreover, increased number of apoptotic events of giant cells in the a…

medicine.medical_specialtyfood.ingredientbiologyImmunologyObstetrics and GynecologyContext (language use)Embryomedicine.diseasefoodEndocrinologymedicine.anatomical_structureReproductive MedicineApoptosisGiant cellAntiphospholipid syndromeInternal medicineYolkembryonic structuresmedicinebiology.proteinImmunology and AllergyAntibodyYolk sacAmerican Journal of Reproductive Immunology
researchProduct

Bafetinib inhibits functional responses of human eosinophils in vitro

2012

Eosinophils play a prominent role in the process of allergic inflammation. Non-receptor associated Lyn tyrosine kinases generate key initial signals in eosinophils. Bafetinib, a specific Abl/Lyn tyrosine kinase inhibitor has shown a potent antiproliferative activity in leukemic cells, but its effects on eosinophils have not been reported. Therefore, we studied the effects of bafetinib on functional and mechanistic responses of isolated human eosinophils. Bafetinib was more potent than non-specific tyrosin kinase comparators genistein and tyrphostin inhibiting superoxide anion triggered by N-formyl-Met-Leu-Phe (fMLF; 100 nM) (−log IC50=7.25±0.04 M; 6.1±0.04 M; and 6.55±0.03 M, respectively).…

medicine.medical_specialtymedicine.drug_classFarmacologíaGenisteinApoptosisPharmacologyBiologyTyrosine-kinase inhibitorAllergic inflammationchemistry.chemical_compoundCell MovementSuperoxidesLYNInternal medicinemedicineHumansProtein Kinase InhibitorsPeroxidasePharmacologyKinaseEosinophil Cationic ProteinGranulocyte-Macrophage Colony-Stimulating FactorEosinophilLeukotriene C4Respiratory burstEosinophilsN-Formylmethionine Leucyl-PhenylalaninePyrimidinesmedicine.anatomical_structureEndocrinologychemistryCalciumInterleukin-5Tyrosine kinaseEuropean Journal of Pharmacology
researchProduct

Possible Pathogenetic Relevance of Interleukin-1beta in "Destructive" Organ-specific Autoimmune Disease (Hashimoto's Thyroiditis)

1999

Thyroid follicular cells (TFC) abundantly express a variety of immunologically relevant surface molecules in Hashimoto's thyroiditis (HT), for example, MHC antigens and adhesion molecules such as ICAM-1. Cytokines produced by infiltrating type 1 helper and cytotoxic T cells are importantly involved in de novo expression or up-regulation of such molecules. We recently demonstrated that TFC from HT patients almost invariably bear on their surface two additive functional molecules: Fas/Apo1/CD95, an important participant in apoptosis, and B7.1, a member of a family of "co-stimulatory" molecules that are crucial for efficient antigen presentation. To date, 12 out of 14 surgical HT thyroid speci…

medicine.medical_specialtymedicine.medical_treatmentAntigen presentationThyroid Glandmedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyFas ligandAutoimmunityHistory and Philosophy of ScienceInternal medicinemedicineHumansCytotoxic T cellfas ReceptorChemistryGeneral NeuroscienceThyroiditis AutoimmuneInterleukinFas receptorMolecular biologyGraves DiseaseRecombinant ProteinsCytokineEndocrinologyApoptosisB7-1 AntigenCytokinesInterleukin-1Annals of the New York Academy of Sciences
researchProduct

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

2013

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth an…

medicine.medical_treatmentCancer TreatmentGene ExpressionApoptosisPharmacologyBiochemistryTargeted therapy0302 clinical medicineMolecular Cell Biology0303 health sciencesSulfonamidesMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionQLiver NeoplasmsRDrug SynergismGenomicsSorafenib3. Good healthGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMedicineLiver cancermedicine.drugResearch ArticleBiotechnologySignal TransductionSorafenibNiacinamideProgrammed cell deathCarcinoma HepatocellularScienceBlotting WesternBiologyMolecular Genetics03 medical and health sciencesCell Line TumorGastrointestinal TumorsmedicineIn Situ Nick-End LabelingHumansneoplasmsBiology030304 developmental biologyCell ProliferationDNA PrimersHuman liver cancer Apoptosis Sorafenib Celecoxib anti-proliferative effectsCell growthGene Expression ProfilingPhenylurea CompoundsComputational BiologyCancers and NeoplasmsHepatocellular CarcinomaChemotherapy and Drug Treatmentmedicine.diseaseMicroarray Analysisdigestive system diseasesGene expression profilingApoptosisCell cultureCelecoxibPyrazolesGenome Expression AnalysisPLoS ONE
researchProduct

Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation

2021

Abstract The proteasome inhibitor bortezomib induces apoptosis in multiple myeloma cells and has transformed patient outcome. Using in vitro as well as in vivo immunodeficient and immunocompetent murine multiple myeloma models, we here show that bortezomib also triggers immunogenic cell death (ICD), characterized by exposure of calreticulin on dying multiple myeloma cells, phagocytosis of tumor cells by dendritic cells, and induction of multiple myeloma–specific immunity. We identify a bortezomib-triggered specific ICD gene signature associated with better outcome in two independent cohorts of patients with multiple myeloma. Importantly, bortezomib stimulates multiple myeloma cell immunogen…

medicine.medical_treatmentIFNBortezomibMiceImmune systemimmune system diseaseshemic and lymphatic diseasesimmunogenic cell deathmedicineAnimalsHumansbortezomib myelomaMultiple myelomaBortezomibbusiness.industryImmunityMembrane ProteinsGeneral MedicineImmunotherapymedicine.diseaseNucleotidyltransferasesStingApoptosisCancer researchProteasome inhibitorImmunogenic cell deathMultiple MyelomabusinessSignal TransductionSTINGmedicine.drugBlood Cancer Discovery
researchProduct